|
| 奥硝唑注射液静脉给药不良反应的Meta分析 |
| Meta analysis of Adverse Reaction Induced by Ornidazole Injection |
| |
| DOI： |
| 中文关键词: 奥硝唑注射液 药品不良反应 Meta分析 亚组分析 |
| 英文关键词:Ornidazole injection Adverse drug reaction Meta analysis Subgroup analysis |
| 基金项目: |
|
| 摘要点击次数: 936 |
| 全文下载次数: 1072 |
| 中文摘要: |
| 摘 要 目的:采用Meta分析方法对奥硝唑注射液静脉给药的不良反应进行系统分析，为奥硝唑注射液临床合理应用和上市后再评价提供参考。方法：计算机检索中文数据库CNKI、VIP、CMCI、SinoMed、万方数据库以及外文数据库PubMed，Cochrane library、OvidSP从建库至2014年12月31日公开发表的有关奥硝唑注射液静脉给药不良反应临床研究文献。根据纳入和排除标准提取资料，采用RevMan 5.2软件，对奥硝唑注射液不良反应发生率按照剂量、疗程和对照药物不同进行Meta亚组分析。结果：符合标准并纳入Meta分析的文献共有18篇。Meta亚组分析结果显示：低剂量（＜500 mg）、高剂量（≥500 mg）、短疗程（≤5 ）、长疗程（＞5 ）、与甲硝唑和替硝唑比较，奥硝唑注射液不良反应发生率均低于对照组（P＜0.01），OR（95%CI）分别为0.32[0.15,0.65]、0.41[0.30,0.58]、0.37[0.24,0.58]、0.41[0.27,0.63]、0.38[0.25,0.59]、0.41[0.26,0.62]；且在剂量为250～1 000 mg，疗程为2～10 d范围内，奥硝唑注射液的不良反应发生率并未随剂量增加和疗程延长而上升。结论：奥硝唑注射液静脉注射治疗口腔厌氧菌感染及妇科厌氧菌感染性疾病，临床不良反应发生率低于甲硝唑、替硝唑；当剂量控制在1 000 mg以下及用药疗程控制在10 d内时，可表现出良好的安全性。 |
| 英文摘要: |
| ABSTRACT Objective:To evaluate the clinical safety of ornidazole injection using Meta analysis and to provide reference for post market evaluation and clinical application of ornidazole injection. Methods:Trials were identified through a computerized literature search of CNKI, VIP, CMCI, SinoMed, Wangfang, PubMed, Cochrane library and OvidSP databases according to inclusion and exclusion criteria. Meta analysis was performed by the statistical software RevMan 5.2. The adverse drug reactions (ADR) of ornidazole injection was analyzed by Meta subgroups according to the dosage, the course of treatment and the control drug. Results: A total of 18 studies were included. Meta subgroup analysis showed: low dose (< 500 mg), high dose(≥500 mg), short course (≤5 d), long course (> 5 d), and compared to metronidazole or tinidazole, the ADRs of ornidazole injection was significantly lower than that of the control group（P＜0.01）, the odds ratio (OR) ( 95%CI ) were 0.32[0.15, 0.65], 0.41[0.30, 0.58], 0.37[0.24,0.58], 0.41[0.27, 0.63],0.38[0.25, 0.59], 0.41[0.26, 0.62]) respectively. In addition, the ADR rate of ornidazole injection did not increase with the dose and duration increase at a dose of 250 1 000 mg and a course of 2 10 days.Conclusion:The ADR of ornidazole injection were significantly lower than the commonly used clinical drugs for anaerobic bacteria infection such as metronidazole, tinidazole in the treatment of oral anaerobic bacteria infection and gynecology anaerobic bacteria infection diseases. It can show a good safety in the dosage below 1 000 mg or the medication within 10 days. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
